Hannah Valantine bought $25k of BBIO
director at BridgeBio Pharma, Inc.. 1,752 shares at an average of $14.24, traded Dec 29, 2021, filed Jun 30, 2025.
Score components
- +15RoleDirector
- 0Trade size$25k at market
- +10Relative to holdingsHoldings up 114%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-091759, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 29, 2021 | POpen-market purchase Common Stock | +1,752 | $14.24 | $25k | 3,294 | Jun 30, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 43Moderate | BridgeBio Pharma, Inc. | Frank McCormick director | $3.9M 74,000 shares | -47% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $4.2M 80,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.3M 26,156 shares | -10% | |
| 62Notable | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $2.1M 42,237 shares | -9% | |
| 40Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $872k 17,353 shares | -4% | |
| 40Moderate | BridgeBio Pharma, Inc. | Charles J Homcy director | $14M 300,000 shares | -25% | |
| 36Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $45k 1,000 shares | -1% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 80,000 shares | -2% | |
| 28Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $841k 17,167 shares | -48% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.